These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22302098)

  • 1. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
    Wong M; Tan N; Zha J; Peale FV; Yue P; Fairbrother WJ; Belmont LD
    Mol Cancer Ther; 2012 Apr; 11(4):1026-35. PubMed ID: 22302098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
    Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
    Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
    Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
    Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Williams J; Lucas PC; Griffith KA; Choi M; Fogoros S; Hu YY; Liu JR
    Gynecol Oncol; 2005 Feb; 96(2):287-95. PubMed ID: 15661210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
    Jain HV; Meyer-Hermann M
    Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
    Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
    Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
    Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
    Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
    Inoue-Yamauchi A; Oda H
    Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
    Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
    Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
    Vlahovic G; Karantza V; Wang D; Cosgrove D; Rudersdorf N; Yang J; Xiong H; Busman T; Mabry M
    Invest New Drugs; 2014 Oct; 32(5):976-84. PubMed ID: 24894650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
    Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
    J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.